Villadsenvinter6067

The main advantage is that the price is low and easy to market and experiment promotion.Epilepsy, as a kind of neurological disease, is harmful to human mental health. There are many problems in the corresponding drugs and treatment methods, such as poor targeting, side effects and drug resistance. The conventional treatment of epilepsy is mainly focused on its corresponding electrophysiological mechanism to limit the discharge of epileptic focus. However, in the clinical and experimental observation process, this method finds that its corresponding target and direction are easily interfered, and its targeting shows poor directionality. Therefore, based on this, this paper will fully combine the electrophysiological mechanism of epilepsy and brain targeting technology, fully analyze the correlation between miR-181 and epilepsy and other nervous system diseases, and construct the epilepsy cell model to provide new ideas for the target and direction. Finally, we will construct a nanoscale hydrogel targeting the electric field, which can rapidly suppress the discharge and release the therapeutic drugs in epileptic seizures, so as to achieve effective treatment for epilepsy. The experimental results show that the new targeting technology proposed in this paper has obvious effect on the treatment of epilepsy.Spontaneous basilar artery occlusive disease is a disease characterized by thickening of the intima of the bilateral internal carotid artery and the anterior and middle cerebral arteries, gradually narrowing the arterial diameter, and compensatory dilatation of the perforating artery at the base of the brain. Aspirin (acetylsalicylic acid), as a classic non-steroidal anti-inflammatory drug, has been proven to have antiplatelet, anti-inflammatory, and immune-regulating effects. But how to achieve long-term sustained release of aspirin and achieve anti-platelet aggregation remains to be studied. This study intends to build a microsphere sustained-release system to achieve long-term stable and slow release of aspirin drug, thereby achieving a more ideal anti-platelet aggregation effect. The therapeutic effects of three groups of nanoparticle sustained-release drug regimens on platelet aggregation were compared. The results showed that the platelet inhibition rate and NIHSS scores before treatment were compared between the three groups; compared with the other groups, the PLGA group had higher AA and ADP pathway-induced platelet inhibition rates after treatment and lower plasma Lp-PLA2 and NIHSS scores. This shows that aspirin nanoparticle slow-release drugs can effectively increase platelet inhibition rate and improve the antiplatelet ability of patients with spontaneous basilar artery occlusive disease, which is beneficial to promoting prognosis recovery.As a first-line drug widely used in the treatment of leukemia, 6-MP has obvious effects on leukemia. However, 6-MP disadvantages such as poor solubility in water, easy binding with serum proteins, short circulation time, and large toxic and side effects greatly limit the application of 6-MP. For this reason, various 6-MP nano drug-loading systems have been designed to increase the water solubility of 6-MP, extend the circulation time, and increase the bioavailability of 6-MP to a certain extent, reducing its toxic and side effects. However, its therapeutic effect in vivo and in vitro is still far from expectations, and there is a lot of room for improvement. In UUN28589 to solve the above problems encountered in the clinical application of 6-MP, we have tried two ways of polymer prodrugs and drug-loaded vesicles to achieve efficient targeted delivery and treatment of 6-MP. We designed hyaluronic acid (HA)-based gluteal-skin-responsive 6-MP polymer prodrug (HA-GS-MP) for highly effective targeted therapy of acute myeloid leukemia. Hyaluronic acid is a natural polysaccharide, which has excellent biocompatibility and biodegradability, and has a good ability to actively target malignant tumor cells overexpressing the CD44 receptor. 6-MP is connected to the HA chain through a vinyl sulfide bond, which is stable under physiological conditions (no drug release), and under intracellular reducing conditions, the connection bond is broken and 6-MP is quickly released. HA-GS-MP has a simple preparation process, good water solubility, long cycle time, and strong targeting ability. This GSH-responsive CD44 targeted 6-MP polymer prodrug is expected to improve the therapeutic effect on acute myeloid leukemia cells.Oral squamous cell carcinoma has the characteristics of high malignancy, strong invasiveness and special anatomical location. The prognosis of patients is generally poor. Invasion and metastasis of oral squamous cell carcinoma is a complex process involving multiple levels and factors. In order to explore the value of sentinel lymph node biopsy tracked by nano-carbon suspension in the treatment of early oral squamous cell carcinoma, 58 patients with early oral squamous cell carcinoma were selected in this paper. The pathological results of sentinel lymph nodes were analyzed after operation. #link# In this study, the detection rate, sensitivity, accuracy, and false negative rate of the sentinel lymph nodes with the nano-carbon suspension were 95.6%, 86.4%, 92.2%, and 11.4%, respectively. The results show that sentinel lymph node biopsy traced by nano-carbon suspension has certain application value in guiding the treatment of early oral squamous cell carcinoma.Liver diseases seriously endanger people's physical health, especially liver cancer, and its morbidity and mortality have increased year by year. The reason why liver cancer is difficult to cure is that in addition to the low lethality of cancer drugs to cancer cells, another important factor is that the drugs do not have liver targeting, and there is no way to efficiently deliver anti-cancer drugs to the liver lesions. Hepatocytes can specifically recognize galactose, therefore the galactosyl liver-targeted drug carrier can deliver the drug to the liver in a targeted manner, so that the drug can be directed to the liver, reduce the dose and times of drug administration, reduce toxic side effects, and reduce the adverse reactions of patients, which is of great significance for the treatment of liver cancer. In this thesis, paclitaxel long-circulating nano-liposomes targeting liver cancer constructed with galactose as raw materials can improve the pharmacokinetics and tissue distribution of traditional formulations of paclitaxel, and enhance the safety and tumor suppressive effect of paclitaxel in vivo.